Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JS015 Combination Therapy in Gastrointestinal Tumors
ChiCTR2400091501Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Oct 2024
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of JS015 in colorectal adenocarcinoma, rectal adenocarcinoma, gastric adenocarcinoma and 1 more (2 cohorts), sponsored by Shanghai East Hospital. Primary endpoint: Objective response rate. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
JS015
03
Conditions
colorectal adenocarcinomarectal adenocarcinomagastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400091501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091501.